Investing.com - Financial Markets Worldwide
Open in App

SK Bioscience Co Ltd (302440)

Seoul
Currency in KRW
37,050
+300(+0.82%)
Delayed Data·

302440 Income Statement

Period Ending:
2021
31/12
2022
31/12
2023
31/12
2024
31/12
2025
31/12
Total Revenues
929,000.93456,725.87369,505.56267,545.05651,368.34
Total Revenues Growth
--50.84%-19.1%-27.59%+143.46%
Cost Of Revenues
358,967.61217,443.09227,681.2237,465.63576,191.84
Gross Profit
570,033.32239,282.78141,824.3530,079.4275,176.51
Gross Profit Growth
--58.02%-40.73%-78.79%+149.93%
Gross Profit Margin %
61.36%52.39%38.38%11.24%11.54%
Other Operating Expenses, Total
95,813.47124,269.16153,812.12168,510.72198,678.19
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
-+29.7%+23.77%+9.56%+17.9%
47,250.0857,959.6585,743.4271,352.8169,861
46,017.5961,779.6460,811.9286,974.3110,967.18
388.56664.991,417.481,2741,410.87
Operating Income
474,219.86115,013.62-11,987.76-138,431.3-123,501.68
Operating Income Growth
--75.75%-110.42%-1,054.77%+10.78%
EBIT Margin %
51.05%25.18%-3.24%-51.74%-18.96%
Net Interest Expenses
-1,910.412,393.512,157.223,293.176,274.52
Net Interest Expenses Growth
-+225.29%+407.93%-72.91%+90.53%
Interest Expense, Total
-3,426.93-2,460.94-1,398.14-3,684.91-9,399.22
Interest And Investment Income
1,516.524,854.4413,555.356,978.0815,673.74
Other Non Operating Expenses, Total
-2,097.02-12,114.2-5,397.467,611.38-10,056.59
EBT, Excl. Unusual Items
470,212.42105,292.92-5,228.01-127,526.75-127,283.75
Gain (Loss) On Sale Of Assets
23.62-434.6-68.0614,259.1730,979.5
Other Unusual Items, Total
---1,153.64-1.41-
EBT, Incl. Unusual Items
471,128.18141,733.187,327.23-89,106.83-85,860.12
EBT, Incl. Unusual Items Growth
--69.92%-94.83%-1,316.11%+3.64%
EBT, Incl. Unusual Items Margin
50.71%31.03%1.98%-33.31%-13.18%
Income Tax Expense
115,988.919,281.23-14,990.49-38,989.76-29,686.91
Net Income to Company
355,139.28122,451.9522,317.72-50,117.07-56,173.21
Minority Interest
----3,764.13-1,251.27
Net Income
355,139.28122,451.9522,317.72-53,881.2-57,424.48
Net Income Growth
--65.52%-81.77%-341.43%-6.58%
Net Income Margin %
38.23%26.81%6.04%-20.14%-8.82%
Preferred Dividend and Other Adjustments
-----
Net Income to Common Excl. Extra Items
355,139.28122,451.9522,317.72-53,881.2-57,424.48
Basic EPS - Continuing Operations
4,844.071,596.18290.65-697.93-732.77
Basic EPS - Continuing Operations Growth
--67.05%-81.79%-340.13%-4.99%
Diluted EPS - Continuing Operations
4,8101,590290-698-733
Diluted EPS - Continuing Operations Growth
--66.94%-81.76%-340.69%-5.01%
Basic Weighted Average Shares Outstanding
73.3176.7276.7977.278.37
Diluted Weighted Average Shares Outstanding
73.8377.0277.0177.278.37
Dividend Per Share
-----
Dividend Per Share Growth
-----
EBITDA
492,995.16142,250.0322,776.94-89,206.06-32,486.07
EBITDA Growth
--71.15%-83.99%-491.65%+63.58%
EBITDA Margin %
53.07%31.15%6.16%-33.34%-4.99%
EBIT
474,219.86115,013.62-11,987.76-138,431.3-123,501.68
* In Millions of KRW (except for per share items)

FAQ

What was SK Bioscience Co’s revenue at year end?

At the end of the last reported fiscal year, SK Bioscience Co (302440) recorded total revenue of 651,368 million KRW.

How much revenue did SK Bioscience Co report in the most recent quarter?

In its most recent quarterly earnings report, SK Bioscience Co posted revenue of 168,611 million KRW.

What was SK Bioscience Co’s net income for the year?

For the full year, SK Bioscience Co reported net income of -57,424 million KRW.

How much net income did SK Bioscience Co post in the last quarter?

In the most recent quarter, SK Bioscience Co (302440) posted net income of -33,327 million KRW.

What was SK Bioscience Co’s gross profit for the year?

Gross profit for the year was reported at 75,177 million KRW.

How much gross profit did SK Bioscience Co generate last quarter?

SK Bioscience Co recorded gross profit of 14,592 million KRW in its latest quarterly report.

What was SK Bioscience Co’s annual operating income?

For the full year, SK Bioscience Co (302440) reported operating income of -123,502 million KRW.

What was SK Bioscience Co’s operating income last quarter?

Quarterly operating income was -44,535 million KRW.

What was SK Bioscience Co’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at -19,105 million KRW.

What was the quarter-over-quarter change in EBITDA for SK Bioscience Co?

EBITDA changed by 26% million KRW compared to the last quarter.

What is SK Bioscience Co’s most recent gross profit margin?

The latest reported gross profit margin for SK Bioscience Co (302440) is 9% million KRW.

What is SK Bioscience Co’s most recent net income margin?

Net income margin based on recent financials is -20% million KRW.

What is SK Bioscience Co’s most recent EBIT margin?

SK Bioscience Co reported an EBIT margin of -26% million KRW based on current figures.

How did SK Bioscience Co’s revenue change compared to the previous quarter?

Revenue changed by -8% million KRW compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for SK Bioscience Co?

In the latest quarter, gross profit changed by 204% million KRW from the previous quarter.
Install Our App
Follow us
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.